Low molecular weight heparin for the prevention of deep venous thrombosis:: A suitable monitoring in elderly patients?

被引:15
作者
Mahé, I
Drouhet, L
Chassany, O
Grenard, AS
Caulin, C
Bergmann, JF
机构
[1] Hop Lariboisiere, Serv Med A, F-75010 Paris, France
[2] Hop Lariboisiere, Lab Hematol Biol, F-75010 Paris, France
关键词
low molecular weight heparin; deep vein thrombosis; elderly; anti-Xa activity;
D O I
10.1159/000065216
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monitoring of anti-Xa activity (aXa) levels is not routinely required in patients receiving enoxaparine at prophylactic dosages, since aXa is supposed to stay below the manufacturer's recommended range in patients treated for venous thrombosis (0.5-1 IU/ml). In order to aXa in elderly subjects receiving prophylactic enoxaparin, 68 consecutive patients (mean age 82.5 +/- 10.7 years) hospitailized in a medical department receiving 4,000 IU enoxaparin daily subcutaneously for the prevention of venous thromboembolic disease were studied. After the first injection of enoxaparin, the aXa of 57.4% patients was superior to 0.5 IU/ml while 69.4% had an aXa higher than 0.5 after 8.4 +/- 1.2 days. A negative relationship between aXa and body weight and a trend towards a positive correlation between aXa and age but not with creatinine clearance were noted. Our findings question the opportunity to monitor aXa in elderly patients receiving 4,000 IU enoxaparin as antithrombotic prophylaxis. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:134 / 136
页数:3
相关论文
共 15 条
[1]  
BARA L, 2001, THROMB HAEMOST S
[2]   How and when to monitor a patient treated with low molecular weight heparin [J].
Boneu, B ;
de Moerloose, P .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (05) :519-522
[3]   Aging and heparin-related bleeding [J].
Campbell, NRC ;
Hull, RD ;
Brant, R ;
Hogan, DB ;
Pineo, GF ;
Raskob, GE .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (08) :857-860
[4]  
COLLIGNON F, 1995, THROMB HAEMOSTASIS, V73, P630
[5]   Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety [J].
Hirsh, J ;
Warkentin, TE ;
Shaughnessy, SG ;
Anand, SS ;
Halperin, JL ;
Raschke, R ;
Granger, C ;
Ohman, EM ;
Dalen, JE .
CHEST, 2001, 119 (01) :64S-94S
[6]   IDENTIFICATION AND PRELIMINARY VALIDATION OF PREDICTORS OF MAJOR BLEEDING IN HOSPITALIZED-PATIENTS STARTING ANTICOAGULANT-THERAPY [J].
LANDEFELD, CS ;
COOK, EF ;
FLATLEY, M ;
WEISBERG, M ;
GOLDMAN, L .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (04) :703-713
[7]  
Mismetti P, 1998, THROMB HAEMOSTASIS, V79, P1162
[8]   DISCORDANCE BETWEEN THE ANTI-XA ACTIVITY AND THE ANTITHROMBOTIC ACTIVITY OF AN ULTRALOW MOLECULAR-WEIGHT HEPARIN FRACTION [J].
OCKELFORD, PA ;
CARTER, CJ ;
MITCHELL, L ;
HIRSH, J .
THROMBOSIS RESEARCH, 1982, 28 (03) :401-409
[9]  
Planès A, 1999, THROMB HAEMOSTASIS, V81, P22
[10]   Comparative pharmacokinetics of LMWHs [J].
Samama, MM ;
Gerotziafas, GT .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 :31-38